Close Menu

Note: This article has been updated with additional information from Abbott's earnings call. 

NEW YORK — Abbott reported Wednesday that its fourth quarter diagnostics revenues rose 5 percent year over year.

For the three months ended Dec. 31, the Abbott Park, Illinois-based firm reported overall revenues of $8.31 billion, up 7 percent from $7.77 billion a year ago and beating the consensus Wall Street estimate of $8.26 billion. Organic sales, which excluded the impact of foreign exchange, grew 9 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.